What is Bausch Health Companies Inc's earnings per share (EPS)?

Bausch Health Companies Inc (BHC) reported diluted earnings per share of $0.42 for fiscal year 2025. This represents a 423.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bausch Health Companies Inc Financials

BHC

Trailing 12 months to June 30, 2026

Revenue $10.9B +10.1% YoY

Net Income -$1.1B -1220.4% YoY

EPS (Diluted) -$2.96 -1238.5% YoY

Free Cash Flow $1.4B +28.3% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 30, 2026 Currency USD FYE December

Bausch Health Companies Inc (BHC) reported $10.9B in revenue over the twelve months to Jun 30, 2026, up 10.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BHC FY2025 2026-04-30

Debt service still dictates the economics even as operating improvement finally pushed Bausch Health back to profitability in FY2025.

FY2025's return to positive net income is less clean than it looks, because operating cash flow fell from $1.6B to $1.4B. Free cash flow also slipped from $1.3B to $1.0B, so the crossover to profit reflected improving accounting earnings more than stronger cash conversion.

Interest expense of $1.6B sat just below operating income of $1.8B in FY2025, which means creditors still capture most of the operating lift before it reaches the bottom line. The business is therefore improving operationally faster than it is repairing the balance sheet, which helps explain why net margin was only 1.5% despite much better operating profitability.

Near-term liquidity improved as the current ratio moved from 0.9x to 1.5x between FY2024 and FY2025, reversing the prior year's short-term squeeze. But long-term debt still stood at $20.6B and equity remained at -$554M, so the balance sheet looks less tight in the short run without becoming lightly financed.

Financial Health Signals

Financial Health Score 51/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Bausch Health Companies Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Bausch Health Companies Inc has an operating margin of 17.7%, meaning the company retains $18 of operating profit per $100 of revenue. This strong profitability earns a score of 74/100, reflecting efficient cost management and pricing power. This is up from 16.1% the prior year.

Growth

Bausch Health Companies Inc's revenue grew 6.7% year-over-year to $10.3B, a solid pace of expansion. This earns a growth score of 61/100.

Leverage

Liquidity

Bausch Health Companies Inc's current ratio of 1.47 indicates adequate short-term liquidity, earning a score of 39/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Bausch Health Companies Inc converts 9.8% of revenue into free cash flow ($1.0B). This strong cash generation earns a score of 69/100.

Returns

Altman Z-Score Distress

0.25

Bausch Health Companies Inc scores 0.25, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/8

Bausch Health Companies Inc passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

8.92x

For every $1 of reported earnings, Bausch Health Companies Inc generates $8.92 in operating cash flow ($1.4B OCF vs $157.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

1.13x

Bausch Health Companies Inc earns $1.13 in operating income for every $1 of interest expense ($1.8B vs $1.6B). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$10.3B

YoY+6.7%

5Y CAGR+5.0%

10Y CAGR-0.2%

Bausch Health Companies Inc generated $10.3B in revenue in fiscal year 2025. This represents an increase of 6.7% from the prior year.

EBITDA

$3.0B

YoY+7.4%

5Y CAGR+3.9%

10Y CAGR-2.8%

Bausch Health Companies Inc's EBITDA was $3.0B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.4% from the prior year.

Net Income

$157.0M

YoY+441.3%

Bausch Health Companies Inc reported $157.0M in net income in fiscal year 2025. This represents an increase of 441.3% from the prior year.

EPS (Diluted)

$0.42

YoY+423.1%

Bausch Health Companies Inc earned $0.42 per diluted share (EPS) in fiscal year 2025. This represents an increase of 423.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.0B

YoY-20.4%

5Y CAGR+4.4%

10Y CAGR-6.8%

Bausch Health Companies Inc generated $1.0B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 20.4% from the prior year.

Cash & Debt

$1.3B

YoY+10.8%

5Y CAGR+16.7%

10Y CAGR+8.2%

Bausch Health Companies Inc held $1.3B in cash against $20.6B in long-term debt as of fiscal year 2025.

Shares Outstanding

371M

YoY+0.7%

5Y CAGR+0.8%

10Y CAGR+0.8%

Bausch Health Companies Inc had 371M shares outstanding in fiscal year 2025. This represents an increase of 0.7% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Operating Margin

17.7%

YoY+1.6pp

5Y CAGR+9.2pp

10Y CAGR+3.0pp

Bausch Health Companies Inc's operating margin was 17.7% in fiscal year 2025, reflecting core business profitability. This is up 1.6 percentage points from the prior year.

Net Margin

1.5%

YoY+2.0pp

5Y CAGR+8.5pp

10Y CAGR+4.3pp

Bausch Health Companies Inc's net profit margin was 1.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 2.0 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Return on Equity

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$629.0M

YoY+2.1%

5Y CAGR+6.8%

10Y CAGR+6.5%

Bausch Health Companies Inc invested $629.0M in research and development in fiscal year 2025. This represents an increase of 2.1% from the prior year.

Capital Expenditures

$397.0M

YoY+17.8%

5Y CAGR+5.6%

10Y CAGR+5.4%

Bausch Health Companies Inc invested $397.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 17.8% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

BHC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BHC quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$10.9B	$10.3B+6.7%	$9.6B+9.9%	$8.8B+7.8%	$8.1B-3.7%	$8.4B+5.1%	$8.0B-6.7%	$8.6B+2.6%	$8.4B-3.9%	$8.7B-9.8%	$9.7B-7.4%	$10.4B+27.3%	$8.2B+42.2%	$5.8B+65.8%	$3.5B+43.4%	$2.4B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2.5B-2.6%	$2.6B+1.6%	$2.5B+16.3%	$2.2B+18.0%	$1.8B+104.0%	$905.1M+32.4%	$683.8M
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$6.2B-12.4%	$7.1B-10.3%	$7.9B+31.3%	$6.0B+53.6%	$3.9B+52.3%	$2.6B+47.7%	$1.7B
R&D Expenses	$663.0M	$629.0M+2.1%	$616.0M+2.0%	$604.0M+14.2%	$529.0M+13.8%	$465.0M+2.9%	$452.0M-4.0%	$471.0M+14.0%	$413.0M+14.4%	$361.0M-14.3%	$421.0M+26.0%	$334.0M+35.8%	$246.0M+56.9%	$156.8M+98.2%	$79.1M+20.4%	$65.7M
SG&A Expenses	$3.4B	$3.4B+4.3%	$3.3B+13.0%	$2.9B+11.1%	$2.6B0.0%	$2.6B+10.9%	$2.4B-7.3%	$2.6B+3.3%	$2.5B-4.2%	$2.6B-8.1%	$2.8B+4.1%	$2.7B+33.3%	$2.0B+55.2%	$1.3B+72.6%	$756.1M+32.1%	$572.5M
Operating Income	$883.0M	$1.8B+17.3%	$1.5B+60.5%	$963.0M+112.1%	$454.0M+0.9%	$450.0M-33.4%	$676.0M+433.0%	-$203.0M+91.5%	-$2.4B-2437.3%	$102.0M+118.0%	-$566.0M-137.1%	$1.5B-23.7%	$2.0B+588.6%	-$409.5M-613.8%	$79.7M-73.4%	$300.0M
Interest Expense	$1.6B	$1.6B+15.6%	$1.4B+4.5%	$1.3B-9.3%	$1.5B+2.7%	$1.4B-7.0%	$1.5B-4.8%	$1.6B-4.3%	$1.7B-8.4%	$1.8B+0.2%	$1.8B+17.5%	$1.6B+61.0%	$971.0M+15.0%	$844.3M+75.3%	$481.6M+44.0%	$334.5M
Income Tax	$361.0M	$247.0M+3.3%	$239.0M+8.1%	$221.0M+166.3%	$83.0M+195.4%	-$87.0M+76.8%	-$375.0M-594.4%	-$54.0M-440.0%	-$10.0M+99.8%	-$4.1B-15251.9%	-$27.0M-120.3%	$133.0M-23.6%	$174.0M+138.6%	-$450.8M-62.0%	-$278.2M-56.7%	-$177.6M
Net Income	-$1.1B	$157.0M+441.3%	-$46.0M+92.2%	-$592.0M-163.1%	-$225.0M+76.3%	-$948.0M-69.3%	-$560.0M+68.7%	-$1.8B+56.9%	-$4.1B-272.4%	$2.4B+199.8%	-$2.4B-736.1%	-$288.0M-132.7%	$880.0M+201.9%	-$863.6M-644.5%	-$116.0M-172.7%	$159.6M
EPS (Diluted)	-$2.96	$0.42+423.1%	-$0.13+92.0%	-$1.62-161.3%	-$0.62+76.5%	-$2.64-67.1%	-$1.58+68.9%	-$5.08+57.0%	-$11.81-272.9%	$6.83+198.4%	-$6.94-716.5%	-$0.85-132.9%	$2.58+195.6%	-$2.70-610.5%	-$0.38-177.6%	$0.49

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$2.9B+13.0%	$2.5B-9.7%	$2.8B+4.3%	$2.7B+6.0%	$2.5B+12.0%	$2.3B-11.7%	$2.6B+2.0%	$2.5B
R&D Expenses	$173.0M+6.1%	$163.0M+1.2%	$161.0M-3.0%	$166.0M+4.4%	$159.0M+11.2%	$143.0M-12.3%	$163.0M+11.6%	$146.0M
SG&A Expenses	$907.0M+5.3%	$861.0M-2.4%	$882.0M+10.9%	$795.0M-11.1%	$894.0M+3.1%	$867.0M+5.7%	$820.0M-3.5%	$850.0M
Operating Income	$740.0M+177.9%	-$950.0M-300.4%	$474.0M-23.4%	$619.0M+39.4%	$444.0M+60.9%	$276.0M-50.5%	$558.0M+75.5%	$318.0M
Interest Expense	$396.0M-1.5%	$402.0M+1.3%	$397.0M-3.6%	$412.0M-11.4%	$465.0M+40.9%	$330.0M-2.1%	$337.0M-2.6%	$346.0M
Income Tax	$88.0M+14.3%	$77.0M-51.6%	$159.0M+329.7%	$37.0M+208.3%	$12.0M-69.2%	$39.0M-64.9%	$111.0M+56.3%	$71.0M
Net Income	$258.0M+118.1%	-$1.4B-1170.5%	-$112.0M-162.6%	$179.0M+20.9%	$148.0M+355.2%	-$58.0M-162.4%	$93.0M+209.4%	-$85.0M
EPS (Diluted)	$0.68+117.8%	-$3.82-1173.3%	-$0.30-162.5%	$0.48+20.0%	$0.40+350.0%	-$0.16-164.0%	$0.25+208.7%	-$0.23

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

BHC Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BHC quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$26.4B-0.6%	$26.5B-3.0%	$27.4B+6.5%	$25.7B-12.0%	$29.2B-6.4%	$31.2B-7.9%	$33.9B+4.2%	$32.5B-13.3%	$37.5B-13.9%	$43.5B-11.1%	$49.0B+86.1%	$26.3B-5.8%	$27.9B+55.6%	$18.0B+36.9%	$13.1B
Current Assets	$6.2B+6.6%	$5.8B+3.2%	$5.6B+31.8%	$4.2B-24.3%	$5.6B+5.0%	$5.3B-23.3%	$7.0B+65.5%	$4.2B-11.3%	$4.7B-6.5%	$5.1B-7.8%	$5.5B+33.3%	$4.1B+6.3%	$3.9B+39.9%	$2.8B+104.6%	$1.4B
Cash & Equivalents	$1.3B+10.8%	$1.2B+24.7%	$947.0M+67.9%	$564.0M-3.1%	$582.0M-3.8%	$605.0M-81.3%	$3.2B+349.8%	$721.0M+0.1%	$720.0M+32.8%	$542.0M-9.2%	$597.0M+84.8%	$323.0M-46.2%	$600.0M-34.5%	$916.1M+458.3%	$164.1M
Inventory	$1.6B+2.1%	$1.6B+3.3%	$1.5B+41.7%	$1.1B+9.8%	$993.0M-9.2%	$1.1B-1.2%	$1.1B+18.5%	$934.0M-10.9%	$1.0B-1.2%	$1.1B-15.6%	$1.3B+41.4%	$889.2M+0.7%	$883.0M+66.2%	$531.3M+49.6%	$355.2M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2.7B+29.4%	$2.1B+23.8%	$1.7B+117.9%	$769.5M+64.2%	$468.5M
Goodwill	$11.3B+1.7%	$11.1B-0.9%	$11.2B-3.2%	$11.5B-7.3%	$12.5B-4.5%	$13.0B-0.6%	$13.1B-0.1%	$13.1B-15.7%	$15.6B-1.3%	$15.8B-14.9%	$18.6B+98.2%	$9.4B-4.0%	$9.8B+89.7%	$5.1B+43.6%	$3.6B
Total Liabilities	$26.0B-3.2%	$26.8B-2.1%	$27.4B+7.9%	$25.4B-13.0%	$29.2B-4.4%	$30.6B-6.5%	$32.7B+10.3%	$29.7B-5.9%	$31.6B-21.6%	$40.3B-6.2%	$42.9B+105.4%	$20.9B-8.1%	$22.7B+59.8%	$14.2B+55.1%	$9.2B
Current Liabilities	$4.2B-38.1%	$6.8B+57.0%	$4.3B+9.2%	$3.9B-24.2%	$5.2B+5.8%	$4.9B-21.4%	$6.2B+62.9%	$3.8B-10.1%	$4.3B+18.3%	$3.6B-32.1%	$5.3B+96.2%	$2.7B+7.8%	$2.5B+37.8%	$1.8B+97.2%	$924.3M
Long-Term Debt	$20.6B+8.7%	$18.9B-13.7%	$21.9B+7.9%	$20.3B-10.2%	$22.7B-5.3%	$23.9B-3.0%	$24.7B+2.4%	$24.1B-4.6%	$25.2B-15.4%	$29.8B-1.4%	$30.3B+98.7%	$15.2B-11.3%	$17.2B+62.9%	$10.5B+61.1%	$6.5B
Total Equity	-$554.0M+56.7%	-$1.3B-25.1%	-$1.0B-47.7%	-$692.0M-552.8%	-$106.0M-119.8%	$535.0M-49.7%	$1.1B-61.1%	$2.7B-53.3%	$5.8B+85.6%	$3.2B-46.7%	$5.9B+11.9%	$5.3B+3.1%	$5.1B+37.7%	$3.7B-5.4%	$3.9B
Retained Earnings	-$9.7B+1.6%	-$9.8B-0.5%	-$9.8B-6.4%	-$9.2B-2.5%	-$9.0B-11.8%	-$8.0B-7.5%	-$7.5B-31.6%	-$5.7B-107.9%	-$2.7B+46.9%	-$5.1B-86.5%	-$2.8B-14.7%	-$2.4B+26.9%	-$3.3B-38.3%	-$2.4B-16.8%	-$2.0B

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$24.8B+1.2%	$24.5B-7.1%	$26.4B-1.7%	$26.8B-1.6%	$27.3B+3.2%	$26.4B-0.4%	$26.5B-0.1%	$26.5B
Current Assets	$6.5B+9.1%	$6.0B-2.9%	$6.2B-1.5%	$6.2B-4.1%	$6.5B+13.6%	$5.7B-0.7%	$5.8B+7.9%	$5.4B
Cash & Equivalents	$1.8B+40.5%	$1.3B-0.8%	$1.3B+0.1%	$1.3B-24.3%	$1.7B+52.3%	$1.1B-4.0%	$1.2B+64.3%	$719.0M
Inventory	$1.6B+0.1%	$1.6B-1.7%	$1.6B+1.9%	$1.6B-3.4%	$1.7B+2.6%	$1.6B+1.1%	$1.6B-3.6%	$1.7B
Goodwill	$9.8B-0.1%	$9.8B-13.0%	$11.3B-0.1%	$11.3B-0.1%	$11.3B+1.3%	$11.2B+0.6%	$11.1B-0.8%	$11.2B
Total Liabilities	$25.6B+0.1%	$25.6B-1.6%	$26.0B-1.8%	$26.5B-2.4%	$27.1B+1.7%	$26.7B-0.7%	$26.8B+0.2%	$26.8B
Current Liabilities	$4.5B+0.3%	$4.5B+8.4%	$4.2B-12.8%	$4.8B-3.7%	$5.0B+16.9%	$4.3B-37.0%	$6.8B+49.8%	$4.5B
Long-Term Debt	$19.9B0.0%	$19.9B-3.5%	$20.6B+0.6%	$20.5B-1.9%	$20.9B-1.7%	$21.2B+12.1%	$18.9B-10.0%	$21.1B
Total Equity	-$1.8B+14.0%	-$2.1B-271.7%	-$554.0M+1.9%	-$565.0M+26.0%	-$764.0M+35.4%	-$1.2B+7.5%	-$1.3B-8.9%	-$1.2B
Retained Earnings	-$10.8B+2.3%	-$11.1B-14.7%	-$9.7B-1.2%	-$9.6B+1.8%	-$9.7B+1.5%	-$9.9B-0.6%	-$9.8B+0.9%	-$9.9B

Not reported in any period shown, so not listed: Accounts Receivable.

BHC Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BHC quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	$1.8B	$1.4B-12.3%	$1.6B+54.7%	$1.0B+241.8%	-$728.0M-151.1%	$1.4B+28.4%	$1.1B-26.0%	$1.5B0.0%	$1.5B-34.5%	$2.3B+9.7%	$2.1B-7.5%	$2.3B-2.4%	$2.3B+121.9%	$1.0B+58.7%	$656.6M+2.5%	$640.5M
Capital Expenditures	$369.0M	$397.0M+17.8%	$337.0M+56.7%	$215.0M-1.4%	$218.0M-19.0%	$269.0M-10.9%	$302.0M+11.9%	$270.0M+72.0%	$157.0M-8.2%	$171.0M-27.2%	$235.0M0.0%	$235.0M-19.5%	$292.0M+153.3%	$115.3M+7.2%	$107.6M+83.9%	$58.5M
Free Cash Flow	$1.4B	$1.0B-20.4%	$1.3B+54.2%	$817.0M+186.4%	-$946.0M-181.8%	$1.2B+43.0%	$809.0M-34.3%	$1.2B-8.4%	$1.3B-36.6%	$2.1B+14.4%	$1.9B-8.4%	$2.0B+0.1%	$2.0B+118.0%	$926.7M+68.8%	$549.0M-5.7%	$582.0M
Investing Cash Flow	-$597.0M	-$595.0M-31.1%	-$454.0M+78.8%	-$2.1B-607.9%	-$303.0M-174.1%	$409.0M+256.7%	-$261.0M+37.7%	-$419.0M-113.8%	-$196.0M-106.8%	$2.9B+2409.6%	-$125.0M+99.2%	-$15.6B-15477.0%	-$100.0M+98.1%	-$5.4B-81.4%	-$3.0B	N/A
Financing Cash Flow	-$1.1B	-$742.0M+14.5%	-$868.0M-158.8%	$1.5B+411.2%	-$474.0M+68.7%	-$1.5B+34.0%	-$2.3B-259.0%	$1.4B+206.7%	-$1.4B+72.7%	-$5.0B-152.8%	-$2.0B-114.4%	$13.6B+653.8%	-$2.5B-161.1%	$4.0B+31.7%	$3.1B	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$72.0M	$0-100.0%	$55.6M-80.2%	$280.7M-56.1%	$639.2M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$670.0M+191.3%	$230.0M-53.5%	$495.0M+22.2%	$405.0M+40.1%	$289.0M+37.0%	$211.0M-64.9%	$601.0M+48.4%	$405.0M
Capital Expenditures	$77.0M-29.4%	$109.0M+18.5%	$92.0M+1.1%	$91.0M-8.1%	$99.0M-13.9%	$115.0M+8.5%	$106.0M+49.3%	$71.0M
Free Cash Flow	$593.0M+390.1%	$121.0M-70.0%	$403.0M+28.3%	$314.0M+65.3%	$190.0M+97.9%	$96.0M-80.6%	$495.0M+48.2%	$334.0M
Investing Cash Flow	-$93.0M+33.1%	-$139.0M+50.7%	-$282.0M-239.8%	-$83.0M+17.0%	-$100.0M+23.1%	-$130.0M+35.0%	-$200.0M-96.1%	-$102.0M
Financing Cash Flow	-$49.0M+51.0%	-$100.0M+57.4%	-$235.0M+67.3%	-$719.0M-300.8%	$358.0M+345.2%	-$146.0M-271.8%	$85.0M+145.0%	-$189.0M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

BHC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

BHC quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	71.3%-2.1pp	73.4%-2.4pp	75.8%+2.3pp	73.5%+5.5pp	68.0%-6.0pp	74.0%+2.2pp	71.8%
Operating Margin	17.7%+1.6pp	16.1%+5.1pp	11.0%+5.4pp	5.6%+0.2pp	5.3%-3.1pp	8.4%+10.8pp	-2.4%+26.1pp	-28.4%-29.6pp	1.2%+7.0pp	-5.9%-20.5pp	14.6%-9.8pp	24.4%+31.5pp	-7.1%-9.4pp	2.3%-10.1pp	12.4%
Net Margin	1.5%+2.0pp	-0.5%+6.3pp	-6.8%-4.0pp	-2.8%+8.5pp	-11.2%-4.3pp	-7.0%+13.8pp	-20.8%+28.7pp	-49.5%-77.0pp	27.6%+52.4pp	-24.9%-22.1pp	-2.8%-13.5pp	10.7%+25.7pp	-15.0%-11.6pp	-3.3%-9.9pp	6.6%
Return on Equity	N/A	N/A	N/A	N/A	N/A	-104.7%+63.5pp	-168.2%-16.6pp	-151.6%-192.7pp	41.1%+117.5pp	-76.4%-71.5pp	-4.9%-21.5pp	16.7%+33.5pp	-16.9%-13.7pp	-3.1%-7.2pp	4.1%
Return on Assets	0.6%+0.8pp	-0.2%+2.0pp	-2.2%-1.3pp	-0.9%+2.4pp	-3.3%-1.5pp	-1.8%+3.5pp	-5.3%+7.5pp	-12.8%-19.2pp	6.4%+11.9pp	-5.5%-4.9pp	-0.6%-3.9pp	3.4%+6.4pp	-3.1%-2.4pp	-0.7%-1.9pp	1.2%
Current Ratio	1.47+0.6x	0.86-0.4x	1.30+0.2x	1.080.0x	1.080.0x	1.090.0x	1.120.0x	1.100.0x	1.11-0.3x	1.41+0.4x	1.04-0.5x	1.530.0x	1.550.0x	1.52+0.1x	1.47
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	44.72+21.5x	23.20+14.4x	8.81+4.5x	4.31-5.2x	9.47+4.3x	5.12+2.2x	2.88-0.5x	3.35+0.5x	2.83+1.2x	1.66
FCF Margin	9.8%-3.3pp	13.1%+3.8pp	9.3%+21.0pp	-11.6%-25.4pp	13.7%+3.6pp	10.1%-4.2pp	14.3%-1.7pp	16.0%-8.3pp	24.3%+5.2pp	19.1%-0.2pp	19.4%-5.3pp	24.6%+8.6pp	16.1%+0.3pp	15.8%-8.2pp	24.0%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Margin	25.9%+63.6pp	-37.6%-54.6pp	17.0%-6.1pp	23.1%+5.5pp	17.5%+5.3pp	12.2%-9.6pp	21.8%+9.1pp	12.7%
Net Margin	9.0%+65.4pp	-56.4%-52.4pp	-4.0%-10.7pp	6.7%+0.8pp	5.9%+8.4pp	-2.6%-6.2pp	3.6%+7.0pp	-3.4%
Return on Assets	1.0%+6.9pp	-5.8%-5.4pp	-0.4%-1.1pp	0.7%+0.1pp	0.5%+0.8pp	-0.2%-0.6pp	0.4%+0.7pp	-0.3%
Current Ratio	1.44+0.1x	1.32-0.2x	1.47+0.2x	1.300.0x	1.310.0x	1.35+0.5x	0.86-0.3x	1.19
FCF Margin	20.8%+16.0pp	4.8%-9.6pp	14.4%+2.7pp	11.7%+4.2pp	7.5%+3.3pp	4.3%-15.1pp	19.3%+6.0pp	13.3%

Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity.

Note: Shareholder equity is negative (-$554.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Indivior Pharmaceuticals Inc. INDV

$4.2B

Hutchmed (China) Limited HCM

$2.1B

Supernus Pharma SUPN

$2.6B

Alvotech ALVO

$1.8B

Amneal Pharmaceuticals Inc AMRX

$6.2B

Where Bausch Health Companies Inc Ranks

Frequently Asked Questions

What is Bausch Health Companies Inc's annual revenue?

Bausch Health Companies Inc (BHC) reported $10.3B in total revenue for fiscal year 2025. This represents a 6.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bausch Health Companies Inc's revenue growing?

Bausch Health Companies Inc (BHC) revenue grew by 6.7% year-over-year, from $9.6B to $10.3B in fiscal year 2025.

Is Bausch Health Companies Inc profitable?

Yes, Bausch Health Companies Inc (BHC) reported a net income of $157.0M in fiscal year 2025, with a net profit margin of 1.5%.

What is Bausch Health Companies Inc's EBITDA?

Bausch Health Companies Inc (BHC) had EBITDA of $3.0B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Bausch Health Companies Inc have?

As of fiscal year 2025, Bausch Health Companies Inc (BHC) had $1.3B in cash and equivalents against $20.6B in long-term debt.

What is Bausch Health Companies Inc's operating margin?

Bausch Health Companies Inc (BHC) had an operating margin of 17.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Bausch Health Companies Inc's net profit margin?

Bausch Health Companies Inc (BHC) had a net profit margin of 1.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Bausch Health Companies Inc's free cash flow?

Bausch Health Companies Inc (BHC) generated $1.0B in free cash flow during fiscal year 2025. This represents a -20.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bausch Health Companies Inc's operating cash flow?

Bausch Health Companies Inc (BHC) generated $1.4B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bausch Health Companies Inc's total assets?

Bausch Health Companies Inc (BHC) had $26.4B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bausch Health Companies Inc's capital expenditures?

Bausch Health Companies Inc (BHC) invested $397.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Bausch Health Companies Inc spend on research and development?

Bausch Health Companies Inc (BHC) invested $629.0M in research and development during fiscal year 2025.

How many shares does Bausch Health Companies Inc have outstanding?

Bausch Health Companies Inc (BHC) had 371M shares outstanding as of fiscal year 2025.

What is Bausch Health Companies Inc's current ratio?

Bausch Health Companies Inc (BHC) had a current ratio of 1.47 as of fiscal year 2025, which is considered adequate.

What is Bausch Health Companies Inc's return on assets (ROA)?

Bausch Health Companies Inc (BHC) had a return on assets of 0.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Why is Bausch Health Companies Inc's debt-to-equity ratio negative or not reported?

Bausch Health Companies Inc (BHC) has negative shareholder equity of -$554.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Bausch Health Companies Inc's Altman Z-Score?

Bausch Health Companies Inc (BHC) has an Altman Z-Score of 0.25, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Bausch Health Companies Inc's Piotroski F-Score?

Bausch Health Companies Inc (BHC) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bausch Health Companies Inc's earnings high quality?

Bausch Health Companies Inc (BHC) has an earnings quality ratio of 8.92x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Bausch Health Companies Inc cover its interest payments?

Bausch Health Companies Inc (BHC) has an interest coverage ratio of 1.13x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Bausch Health Companies Inc?

Bausch Health Companies Inc (BHC) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.